The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage

AHOD (The Australian HIV Observational Database). Time trends in antiretroviral treatment use in Australia, 1997–2000, Venereology 2000;14:162–168. AHOD (The Australian HIV Observational Database). Rates of combination antiretroviral treatment change in Australia, 1997–2000, HIV Med 2002;3:28–36. Becker, 2001, Zidovudine and Stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort, JAIDS, 26, 72, 10.1097/00126334-200101010-00011 Benson, 2001, Structured treatment interruption in HIV infection, AIDS Reader, 11, 99 Cameron, 1998, Ritonavir and Saquinavir combination therapy for the treatment of HIV infection, AIDS, 13, 213, 10.1097/00002030-199902040-00009 Carr, 1998, A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors, AIDS, 12, F51, 10.1097/00002030-199807000-00003 Carr, 2000, A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome, AIDS, 14, F25, 10.1097/00002030-200002180-00001 Correll, 1998, HIV disease progression in Australia in the time of combination antiretroviral therapies, Med. J. Aust., 169, 469, 10.5694/j.1326-5377.1998.tb123370.x Cozzi Lepri, 2001, The virological response to highly active antiretroviral therapy over the fist 24 weeks of therapy according to pre-therapy viral load and the weeks 4–8 viral load, AIDS, 15, 47, 10.1097/00002030-200101050-00008 Cozzi Lepri, 2001, When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study, AIDS, 15, 983, 10.1097/00002030-200105250-00006 CTARC (HIV/AIDS Clinical Trials and Research Committee of the Australian National Council on AIDS, Hepatitis C and Related Diseases). Draft 2001 Australian Antiretroviral Guidelines (edited by Jenny Hoy) October 2001, Available at: http://www.ashm.org.au/uploadFile/GUIDELINES2.pdf. Egger, 1997, Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, Br. Med. J., 315, 1194, 10.1136/bmj.315.7117.1194 Erb, 2000, Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort, Arch. Int. Med., 160, 1134, 10.1001/archinte.160.8.1134 Fatkenheuer, 1997, Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients, AIDS, 11, F113, 10.1097/00002030-199714000-00001 Grabar, 2000, Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor, AIDS, 14, 141, 10.1097/00002030-200001280-00009 Graham, 1998, Studies of Antiretroviral therapy in the Multicenter AIDS Cohort Study, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 17, S9, 10.1097/00042560-199801001-00004 Junghans, 1999, Uniform risk of clinical progression despite differences in utilisation of highly active antiretroviral therapy: Swiss HIV Cohort Study, AIDS, 13, 2547, 10.1097/00002030-199912240-00008 Kaufmann, 1998, Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort, AIDS, 12, 1625, 10.1097/00002030-199813000-00009 Law, 1999, Trends in antiretroviral treatment for people with HIV in Australia: an observational database pilot study, Venereology, 12, 97 Law, 2000, Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection, AIDS, 14, 197, 10.1097/00002030-200001280-00016 Ledergerber, 1999, AIDS related opportunistic illness occurring after initiation of potent antiretroviral therapy, J. Am. Med. Assoc., 282, 2220, 10.1001/jama.282.23.2220 Lundgren, 1997, Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients, JAIDS, 16, 153 Mallal, 2000, Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection, AIDS, 14, 1309, 10.1097/00002030-200007070-00002 Martinez, 2000, Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study, Lancet, 357, 532 Merry, 1997, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients, AIDS, 11, F29, 10.1097/00002030-199704000-00001 Miller, 2000, The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load, AIDS, 14, 2129, 10.1097/00002030-200009290-00009 Miller, 2000, Virological and immunological effects of treatment interruption in HIV-1 infected patients with treatment failure, AIDS, 14, 2857, 10.1097/00002030-200012220-00007 Mocroft, 1998, Changing patterns of mortality across Europe in patients infected with HIV-1, Lancet, 352, 1725, 10.1016/S0140-6736(98)03201-2 Mocroft, 1998, Predictors of viral response and subsequent virological treatment failure in patients with HIV starting a PI, AIDS, 12, 2161, 10.1097/00002030-199816000-00011 Morlat, 2000, Dual nucleoside regimens in non-advanced HIV infection: prospective follow-up of 130 patiens, Aquitaine cohort, 1996–1998, JAIDS, 23, 255, 10.1097/00126334-200003010-00007 Moyle, 2001, Use of HIV protease inhibitors as pharmacoenhancers, AIDS Reader, 11, 87 National Centre in HIV Epidemiology and Clinical Research. Australian HIV Observational Database. Biannual Report, vol. 2, No. 2. December 2001a. Sydney: NCHECR, University of NSW, 2001. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Hepatitis C and sexually transmissible infections in Australia: annual surveillance report 2001b. Sydney: NCHECR, University of NSW, 2001. Neumann, 1999, HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment, AIDS, 13, 677, 10.1097/00002030-199904160-00008 Paredes, 2000, Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study, Arch. Int. Med., 160, 1123, 10.1001/archinte.160.8.1123 Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, For the EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomised trials. AIDS 1999;13:2075–82. Piketty, 1998, Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease, AIDS, 12, 745, 10.1097/00002030-199807000-00011 Rhone, 1998, The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study, AIDS, 12, 619, 10.1097/00002030-199806000-00011 Rosenberg, 2000, Immune control of HIV-1 after early treatment of acute infection, Nature, 407, 523, 10.1038/35035103 Ruiz, 2000, Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression, AIDS, 14, 397, 10.1097/00002030-200003100-00013 Staszewski, 1999, Virological response to protease inhibitor therapy in an HIV clinic cohort, AIDS, 13, 367, 10.1097/00002030-199902250-00009 Tarwater, 2001, Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy, JAIDS, 27, 168, 10.1097/00126334-200106010-00012 Viard, 2001, Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study, J. Infect. Dis., 183, 1290, 10.1086/319678 Weidle, 1999, Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy, AIDS, 13, S61 Yamashita, 2001, Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study, AIDS, 15, 735, 10.1097/00002030-200104130-00009